NurExone Q2FY26 Results: Net loss narrows 9% YoY to US$1.68 million
- Net loss narrowed to US$1.68 million in Q2 2026 from US$1.85 million in Q2 2025
- General and administrative expenses fell 18% YoY to US$0.93 million
- Research and development costs rose to US$0.75 million due to ExoPTEN advancement
- Company secured US$1.2 million via private placements in June and August 2026
- Entered MOUs for U.S. GMP manufacturing and exclusive Mexico distribution rights
*this image is generated using AI for illustrative purposes only.
NurExone Biologic Inc. (TSXV: NRX) reported a narrowed net loss for the second quarter ended June 30, 2026, driven by reduced administrative costs despite higher research spending. The biotechnology firm also secured US$1.2 million in gross proceeds through two private placements to support its working capital and pipeline advancement.
The company posted a net loss of US$1.68 million for the quarter, an improvement from the US$1.85 million loss recorded in the same period of 2025. This reduction was primarily attributable to a decline in general and administrative expenses, which fell to US$0.93 million from US$1.13 million year-ago, aided by lower professional services and legal costs.
Financial Performance
Research and development expenses rose to US$0.75 million from US$0.70 million in Q2 2025, reflecting increased material purchases and development activity for its lead product, ExoPTEN. Net financial expenses remained minimal at US$0.01 million, down from US$0.02 million previously, due to lower foreign currency translation adjustments.
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| R&D Expenses | US$0.75 million | US$0.70 million | +US$0.05 million |
| G&A Expenses | US$0.93 million | US$1.13 million | -US$0.20 million |
| Net Financial Expenses | US$0.01 million | US$0.02 million | -US$0.01 million |
| Net Loss | US$1.68 million | US$1.85 million | -US$0.17 million |
What the Numbers Show
General and administrative expenses constituted approximately 55% of the total operating expenses in Q2 2026, while research and development accounted for the remaining 45%. The divergence between rising R&D spend and falling G&A indicates a strategic shift toward prioritizing clinical pipeline advancement over corporate overhead during this period.
Strategic Developments
NurExone advanced several key commercial and regulatory milestones:
- U.S. Manufacturing: Entered a binding memorandum of understanding with Made Scientific Inc. on August 12, 2026, for GMP manufacturing collaboration. Initial batches are targeted for H1 2027.
- Mexico Distribution: Subsidiary Exo-Top Inc. signed an MOU with ExoLyra LLC on June 24, 2026, securing exclusive rights to market exosome products in Mexico for three years, supported by a US$180,000 exclusivity fee.
- IP Expansion: Received patent grants in Korea and Australia covering ExoPTEN and extracellular vesicle bioproduction.
- Financing: Closed private placements in June and August 2026 raising aggregate gross proceeds of approximately US$1.2 million (C$1.69 million) for general working capital.
How will the transition to GMP manufacturing with Made Scientific in H1 2027 impact NurExone's production costs and scalability for ExoPTEN?
What specific clinical trial milestones or regulatory submissions are expected to be funded by the recent US$1.2 million private placement?
Given the rising R&D expenses, what is the projected timeline for ExoPTEN to reach market-ready status in the U.S. and Mexico?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
